Showing 3621-3630 of 19355 results for "".
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-wclc-2025/37877/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Mastering the Sequence: CELMoDs Across Treatment Lines
https://reachmd.com/programs/cme/mastering-the-sequence-celmods-across-treatment-lines/36570/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityPrimary HPV Screening: A Nurse Practitioner’s Perspective
https://reachmd.com/programs/video-library/primary-hpv-screening-nurse-practitioners-perspective/8593/The following is part of a 3-part-video series addressing clinician-patient interactions related to primary high-risk HPV screening. More specifically, this video represents a typical dialogue between a Nurse Practitioner and her patient as she explains primary high-risk HPV screening to her patientProgress in Breast Cancer Care: Translating SABCS Data Into Practice
https://reachmd.com/programs/cme/progress-in-breast-cancer-care-translating-sabcs-data-into-practice/48989/Learn to integrate the latest data on ADCs in breast cancer into clinical practice, expand treatment options, and apply emerging evidence in real-world care.Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
https://reachmd.com/programs/cme/optimizing-raasimra-therapy-in-patients-with-heart-failure-ckd-and-hyperkalemia-a-microlearning-curriculum-approach/26750/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Safety First: Navigating CELMoD-Associated Toxicities
https://reachmd.com/programs/cme/safety-first-navigating-celmod-associated-toxicities/36571/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityNovel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
https://reachmd.com/programs/cme/novel-ras-targeted-therapy-prevention-monitoring-and-mitigation-of-adverse-events/54123/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Precision Targeting: Matching CELMoDs to the Right Patient With Myeloma
https://reachmd.com/programs/cme/precision-targeting-matching-celmods-to-the-right-patient-with-myeloma/36569/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityCase Management Strategies for Patients with ADPKD – Part 2
https://reachmd.com/programs/cme/case-management-strategies-for-patients-with-adpkd-part-2/13880/This program is no longer availble for credit This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in tMechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
https://reachmd.com/programs/cme/mechanism-driven-gmg-therapy-fcrn-antagonists-and-the-rise-of-precision-neurology/36277/Review FcRn antagonists in gMG, including mechanisms, pivotal trials, and strategies for integrating novel therapies into personalized care.